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LETTERS TO THE EDITOR
Regarding “Subfascial endoscopic perforator vein
surgery combined with saphenous vein ablation:
Results and critical analysis”
I read with interest the article by Bianchi et al (J Vasc Surg
2003;38:67-71). Their data confirm the finding that subfascial
endoscopic vein surgery (SEPS), combined with saphenous vein
ablation, results in shorter and durable healing of leg ulcers.
However, there appear some confusing or alarming state-
ments in the Results section:
1. “The SEPS procedure was uniformly performed in all cases as
described previously.”
2. “A mean of 3 (range, 1-7) perforating veins were ligated and
divided at surgery.”
3. “Perioperative complications occurred in 12 limbs (16%) and
included wound infection (7 limbs), subfascial hematoma (3
limbs), abscess (1 limb), and superficial thrombophlebitis (1
limb). All complications occurred in limbs with C6 disease (P
.04).”
Regarding these three statements, I found the first two confusing,
and the third alarming.
In fact, the first statement is wrong since, at least in the first 23
patients, SEPS was performed without accessing the deep posterior
compartment. This suggests that in these cases incompetent per-
forating veins were certainly missed. In fact, in the second state-
ment the authors affirm that only a mean of three (range 1-7)
incompetent perforating veins were found and interrupted.
The third (and, from my point of view, alarming) statement
regards the unacceptably high rate of complications—more than
20% (!) if we consider only limbs with C6 disease. Overall, the high
rate of infection for a “clean” surgical intervention (since the
incision for the single port access is remote from the ulcer areas)
should be regarded as a contraindication to the surgical treatment
of C6 chronic venous insufficiency patients.
1 Then, one could
indicate for these patients medical treatment of the ulcers to be
administered prior to surgery.
Francesco Rulli, MD
University of Rome Tor Vergata
Rome, Italy
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Reply
We appreciate Dr. Rulli’s comments and hope the following
will answer his queries:
1. The term “uniformly performed” meant only that subfascial
endoscopic perforator vein surgery (SEPS) was performed by
using a single port, open scope technique. We understand how
one could be confused with that word choice since the deep
posterior compartment was not accessed in the first 23 cases.
Some incompetent perforating veins (IPVs) could have been
missed by not exploring the deep posterior compartment. On
the other hand, despite thorough exploration we sometimes
find no IPVs to ligate in the deep posterior compartment.
2. Therefore, the number of ligated IPVs were reported as such.
3. We do not consider the SEPS procedure to be “clean” in the
setting of an active venous ulcer and, as expected, the over-
whelming majority of complications were superficial wound
infections. We do not consider the threat of superficial wound
infection to be a contraindication to surgical treatment. The
other complications occurred early in our experience with the
procedure, and now it is extremely unusual to have anything
other than an occasional superficial wound infection complicate
a SEPS procedure.
Thank you for the opportunity to clarify those issues.
Jeffrey L. Ballard, MD, FACS
Loma Linda University Medical Center
Loma Linda, Calif
doi:10.1016/j.jvs.2003.08.011
Regarding “Venous reflux repair with cryopreserved
vein valves”
The timely article by Negle´n and Raju (J Vasc Surg 2003;37:
552-7) describes their experience in treating deep venous reflux
with cryopreserved vein implantation because repair with autoge-
nous vein was not possible. They noted that, in a large number of
patients with thrombophilia, the transplanted cryopreserved vein
became occluded despite aggressive anticoagulation therapy. We
were surprised that 74% of the supplied cryovalves were incompe-
tent when thawed, requiring transcommisural repair before im-
plantation.
To treat primary incompetence of the common femoral vein,
we have used glutaraldehyde-preserved bovine pericardial mono-
cusp patches, and more recently cryopreserved monocusp patches
made from allograft pulmonary arteries.1,2 Even though these
patients were not “thrombosis prone,” none of our repairs has
thrombosed.2 The fundamental difference between our approach
and that of Negle´n and Raju is that we retain the posterior aspect of
the patient’s own vein. This concept originated after we repaired
femoral veins damaged during extracorporeal membrane oxygen-
ator support by patching them with polytetrafluoroethylene.
Those repairs in which the posterior aspect of the patient’s vein was
retained remained patent without thrombosis. Patency was con-
firmed at duplex scanning and venography.
In patients with primary reflux in whom we have implanted
glutaraldehyde-preserved monocusp patches of bovine pericar-
dium or cryopreserved allograft pulmonary arteries, we do not use
warfarin anticoagulation therapy. Our maintenance regimen is 75
mg of clopidogrel and 81 mg of aspirin, after a loading dose of 300
mg of clopidogrel. This is clearly an indicator that our group of
patients is quite different from the “thrombosis-prone” patients
described by Negle´n and Raju.
It is important to note that the cause of venous ulceration was
primary in more than 95% of our patients, which is different from
what was noted in other reported series, in which there is a
prevalence of deep venous valvular insufficiency secondary to ve-
nous thrombosis. Use of our technique for treatment of secondary
deep venous valvular insufficiency will probably require a radically
different type of anticoagulation protocol to overcome the ten-
dency for development of thrombosis.
Raul Garcı´a-Rinaldi, MD
Centro Medico Ramon Emeterio Betances
Mayaguez, Puerto Rico
1139
REFERENCES
1. Garcı´a-Rinaldi R, Revuelta JM, Martı´nez MJ, et al. Femoral vein valve
incompetence: treatment with a xenograft monocusp patch: preliminary
report. J Vasc Surg 1986;3:932-5.
2. Garcı´a-Rinaldi R, Soltero ER, Carballido J, et al. Implantation of cryo-
preserved pulmonary allograft monocusp patch to treat nonthrombotic
femoral vein incompetence. Tex Heart Inst J 2002;29:92-9.
doi:10.1016/S0741-5214(03)00915-7
Reply
We read Dr Garcı´a-Rinaldi’s letter with interest, and are
familiar with his report published in 2002. In his letter, Dr Garcı´a-
Rinaldi points out the fundamental difference in the patient pop-
ulations that received treatment, which makes any comparison of
patency and competency of the two techniques invalid. The mo-
nocusp patch is used in a group of patients with primary insuffi-
ciency without previous thrombotic events. In contrast, we at-
tempt to control reflux in patients with severe thrombotic disease.
Our group of patients is not only “thrombosis prone,” but the
target vessel is severely diseased with thickened wall, often trabec-
ulated lumen, and scarred, uneven endothelium. Retaining the
posterior aspect of the patient’s own vessel wall might be prudent
in nonthrombotic disease with smooth endothelium enabling
good apposition of the monocusp, but it might prove inadequate
in a postthrombotic vessel.
We recognize Dr Garcı´a-Rinaldi’s excellent short-term results
with the cryopreserved monocusp patch in primary disease, and
look forward to evaluation of this technique when used to control
reflux in postthrombotic disease.
Peter Negle´n, MD, PhD
Seshadri Raju, MD
River Oaks Hospital
Jackson, Miss
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Regarding “Is there an increased risk for DVT with
the VNUS closure procedure?”
In a letter to the Editor, Komenaka and Nguyen (J Vasc Surg
2002;36:1311) reported that deep venous thrombosis developed
in 2 of 29 patients after varicose vein ablation with the VNUS
closure device. This 6.8% incidence seems high, compared with the
generally reported 0.8% to 1.3% risk for deep venous thrombosis
with varicose vein treatment.1,2
The US Food and Drug Administration (FDA) approved the
VNUS closure catheter in 1998 as “substantially equivalent to”
seven older devices. Thus safety data based on results of trials in
human beings for this class II approval were not submitted. The
closure device generates interest for improving conventional vari-
cose vein surgery, but, in the absence of controlled trials, reports of
its advantages seem premature.3 The FDA Manufacturer and User
Facility Device Experience Database (MAUDE)4 presently in-
cludes 20 reports of serious adverse events after use of this device.
As a result of gross underreporting, the FDA estimates this to
represent less than 1% of actual serious adverse events occurring in
clinical practice.
Only one report (5%) describes a manufacturing defect,
whereas 19 reports (95%) involve deep vein thrombosis or ascend-
ing thrombosis. Three reports (16%) mention pulmonary embo-
lism, but because of patients lost to follow-up, mortality could not
be assessed. Most patients (n 12; 63%) received anticoagulation
therapy, with or without thrombectomy or saphenofemoral junc-
tion ligation. Faulty technique was reported in only two patients
(10%); it is surprising that the procedure was declared successful,
“irrespective of the thrombosis,” in nine patients (47%).
These reports in the MAUDE database raise substantial con-
cern about the incidence of deep vein thrombosis after VNUS
closure or radiofrequency ablation of varicose veins, which must be
carefully addressed by the FDA and the manufacturer.
R. C. Guptan, MD
Venous Research Foundation
Schaumburg, Ill
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Regarding “Carotid artery stenting: Analysis of data
for 105 patients at high risk”
I read with interest the article by Hobson et al (J Vasc Surg
2003;37:1234-9) regarding carotid artery stenting (CAS). I be-
lieve the article makes a further, important contribution to evalu-
ating this procedure.
The article suggests some concerns about CAS. The technique
involves some issues that must be debated, including indications,
cerebral protection, and immediate and long-term results.
I would like to focus on indications for the technique. Hobson
and colleagues suggest that CAS can be used in patients at poor or
high surgical risk, including those with concomitant morbid con-
ditions, recurrent stenosis, stenosis after cervical irradiation, and
anatomic features of carotid stenosis.
From this point of view, CAS is an alternative to carotid
endarterectomy (CEA), and the two should be compared. In
comparing these procedures, we must take into account the cur-
rent results of CEA. I agree with Hobson and colleagues regarding
preference for CAS in patients with post-irradiation stenosis and
recurrent stenosis. As stressed by the authors, CEA results for
recurrent stenosis were not as good as for primary stenosis. To
indications for CAS, I would add carotid stenosis with some
anatomic characteristics, for example, stenosis involving the distal
extracranial internal carotid artery. When considering CAS in the
subgroup of patients with comorbid conditions, I believe some
caution is needed. In the report by Hobson and colleagues, CAS
was followed by complications in 2.85% of patients. After nonin-
vasive diagnostic testing, including duplex scanning and, in some
cases, multisection computed tomography angiography or mag-
netic resonance imaging angiography, CEA can be performed with
the patient under local anesthesia. This avoids complications
caused by arteriography, which is necessary for CAS and was
responsible for complications in 4.7% of patients. Local anesthesia
has significant advantages over general anesthesia, such as capabil-
ity for neurologic monitoring, lower incidence of stroke,1 stable
cardiovascular condition,2 and better cerebral perfusion during
carotid artery occlusion.3
These observations are supported by experience at our insti-
tution.4 The cumulative incidence of perioperative stroke and
mortality was 0.7% in a series of 147 patients with symptomatic or
asymptomatic stenosis who were operated on under local anesthe-
sia. This series included numerous patients with comorbid condi-
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